REVIEW

AMPK as a mediator of hormonal signalling

Chung Thong Lim, Blerina Kola and Márta Korbonits

Endocrinology, Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK

(Correspondence should be addressed to M Korbonits; Email: m.korbonits@qmul.ac.uk)

Abstract

AMP-activated protein kinase (AMPK) is a key molecular player in energy homeostasis at both cellular and whole-body levels. AMPK has been shown to mediate the metabolic effects of hormones such as leptin, ghrelin, adiponectin, glucocorticoids and insulin as well as cannabinoids. Generally, activated AMPK stimulates catabolic pathways (glycolysis, fatty acid oxidation and mitochondrial biogenesis) and inhibits anabolic pathways (gluconeogenesis, glycogen, fatty acid and protein synthesis), and has a direct appetite-regulating effect in the hypothalamus. Drugs that activate AMPK, namely metformin and thiazolidinediones, are often used to treat metabolic disorders. Thus, AMPK is now recognised as a potential target for the treatment of obesity and associated co-morbidities.

Journal of Molecular Endocrinology (2010) **44**, 87–97

Introduction

AMP-activated protein kinase (AMPK) has emerged as a key molecular player in energy homeostasis at both cellular and whole-body levels (Kahn *et al.* 2005). Initially, AMPK was shown to have lipid-related effects: it inactivates acetyl-CoA carboxylase (ACC; Carlson & Kim 1973) and 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase (Beg *et al.* 1973), the key regulatory enzymes of fatty acid and cholesterol synthesis. Later, the role of AMPK in carbohydrate and protein metabolism, cell cycle regulation and mitochondrial biogenesis was also described. AMPK is an evolutionarily conserved serine/threonine kinase with a catalytic α -subunit and regulatory β - and γ -subunits, forming a heterotrimeric complex. The upstream regulation of AMPK is summarised in Figs 1 and 2.

Role of AMPK in the central control of appetite

AMPK is expressed throughout the brain: all isoforms are expressed in neuronal tissues including areas that are involved in the control of food intake and neuroendocrine function, such as the hypothalamus and the hindbrain (Turnley *et al.* 1999, Kola 2008). In the last 5 years, AMPK has emerged as a nutrient and glucose sensor in the hypothalamus (Momcilovic *et al.* 2006). Hypothalamic AMPK activity is increased during

fasting and decreased during refeeding (Minokoshi *et al.* 2004). Pharmacological activation of AMPK in the rodent hypothalamus with 5-aminoimidazole-4-carboxamide riboside (AICAR) causes an increase in food intake (Xue & Kahn 2006). Alteration in ventromedial hypothalamic AMPK activity with recombinant adenoviruses expressing dominant negative (DN) or constitutively active (CA) AMPK- $\alpha 1/\alpha 2$ subunit (Minokoshi *et al.* 2004) changed body weight and food intake. DN-AMPK adenovirus-treated mice ate less and had lower body weight compared with control mice. DN-AMPK mice also had decreased neuropeptide Y (NPY) and agouti-related peptide (AgRP) mRNA levels in the arcuate nucleus (ARC) under *ad libitum* fed conditions. In contrast, CA-AMPK adenovirus-treated mice ate significantly more and had higher body weight with increased expression of NPY and AgRP mRNA in ARC, as well as increased orexigenic melanin-concentrating hormone expression in lateral hypothalamus. This suggests that high AMPK activity enhances orexigenic signals, whereas low AMPK activity suppresses these signals under *ad libitum* fed conditions. In agreement with this, deletion of AMPK $\alpha 2$ in AgRP neurons led to the development of an age-dependent lean phenotype.

Peripheral hormones from the gastrointestinal tract (peptide YY, ghrelin, cholecystokinin, glucagon-like peptide 1 (GLP-1) and oxyntomodulin) and adipose tissue (leptin, resistin and adiponectin) are important in influencing the activity of the appetite-regulating

Figure 1 AMPK regulation: AMPK's upstream kinases phosphorylate the Thr172 residue of the α -kinase subunit. *LKB1*, a tumour-suppressor gene (Hawley *et al.* 2003, Woods *et al.* 2003, Shaw *et al.* 2004), calmodulin kinase kinase (CaMKK; Hawley *et al.* 2005, Hurley *et al.* 2005, Woods *et al.* 2005), and the recently described kinases transforming growth factor- β -activated kinase (TAK1) and ataxia telangiectasia mutated (ATM) are the known AMPK kinases. CaMKK2 (also known as CaMKK β) is expressed primarily in the brain, suggesting that this Ca^{2+} -mediated pathway may be operating in neurons (Towler & Hardie 2007). TAK1 is a member of the mitogen-activated protein kinase kinase family and is reported to phosphorylate AMPK in HeLa cells, which lack *LKB1* expression (Momcilovic *et al.* 2006). ATM, which stimulates mitochondrial biogenesis in response to double-stranded DNA breaks, also can phosphorylate AMPK (Fu *et al.* 2008). A rise in AMP:ATP ratio activates AMPK i) allosterically and ii) by inhibition of dephosphorylation by protein phosphatases (Hardie *et al.* 1999, Sanders *et al.* 2007). Recently, it has been shown that AMPK can be regulated directly by glycogen and may act as a glycogen sensor (McBride *et al.* 2009). The α 1–6 linkage-branched forms of glycogen allosterically inhibit AMPK more potently than the linear α 1–4-linked forms (Carling 2009, McBride *et al.* 2009). In addition to the allosteric effect, the branched glycogen also inhibits *LKB1*- or CaMKK2-induced Thr172 phosphorylation, while dephosphorylation is not affected by glycogen. A new model of AMPK regulation, which is independent of AMP, has recently been identified. It is shown that cell death-inducing DFFA-like effector- α (Cidea) forms a complex with the β -subunit of AMPK, eliciting a ubiquitination-mediated degradation of AMPK (Qi *et al.* 2008).

neuronal populations in the hypothalamus. In addition, a number of these hormones have been shown to influence AMPK activity. In the short term, anorectic agents such as glucose, GLP-1 and oxyntomodulin decrease hypothalamic AMPK activity (Andersson *et al.* 2004, Minokoshi *et al.* 2004, Seo *et al.* 2008), leading to reduction in food intake during satiation, while orexigenic agents such as ghrelin lead to AMPK activation and increased food intake (Andersson *et al.* 2004, Kola *et al.* 2005). In the long term, the circulating anorectic insulin and leptin determine the energy and adiposity profile.

The hypothalamus is not the only location in the brain important for appetite regulation. Emerging data suggest that the nucleus tractus solitarius (NTS) in the hindbrain also has an important role. Fasting increases AMPK activity in the NTS and leptin inhibits it (Hayes *et al.* 2009a). Ghrelin is known to activate neurons in

the NTS (Date *et al.* 2006). GLP-1 (7–36) amide, an anorectic hormone, acts both in the hypothalamus and the NTS (Goldstone *et al.* 2000, Seo *et al.* 2008, Hayes *et al.* 2009b).

Role of AMPK in peripheral tissues

AMPK is ubiquitously expressed and plays an important role in the peripheral metabolism of the skeletal muscle, liver, fat, myocardium and other tissues. In general, activated AMPK switches on catabolic processes that produce ATP and switches off ATP-consuming processes, thus restoring the AMP:ATP ratio.

AMPK plays a key role in regulating lipid metabolism. Activated AMPK phosphorylates and inhibits ACC1 and HMG-CoA, decreases fatty acid synthase (FAS) expression and activates malonyl-CoA carboxylase, thereby leading to a decrease in fatty acid and cholesterol synthesis (Woods *et al.* 2000, Kahn *et al.* 2005, Lopez *et al.* 2007). Activated AMPK stimulates fatty acid oxidation by decreasing malonyl-CoA levels through the inhibition of ACC2 (Merrill *et al.* 1997, Kahn *et al.* 2005, Lopez *et al.* 2007). This leads to an increase in carnitine palmitoyltransferase 1 (CPT1) activity and the subsequent activation of fatty acid oxidation (Kahn *et al.* 2005, Lopez *et al.* 2007). The decreased AMPK activity in visceral fat could enhance lipolysis as well as lipogenesis, although the effect on lipogenesis prevails (Divertie *et al.* 1991, Djurhuus *et al.* 2002). AMPK thus plays a key role in regulating lipid metabolism. AMPK has been suggested to inhibit catecholamine-stimulated lipolysis in adipocytes (Corton *et al.* 1995, Daval *et al.* 2005), thus lowering the plasma level of fatty acids. Activated AMPK also stimulates and upregulates the expression of peroxisome proliferator-activated receptor- γ coactivator-1 α , which consequently increases mitochondrial biogenesis (Terada *et al.* 2002, Zong *et al.* 2002).

AMPK also regulates glucose homeostasis. Activation of AMPK by contraction in fast-twitching muscles increases hexokinase II expression (Holmes *et al.* 1999), and enhances glucose uptake through the translocation of glucose transporter 4 (GLUT4) to the cell membrane and the upregulation of *Glut4* gene expression (Holmes *et al.* 1999, Derave *et al.* 2000, Wright *et al.* 2005). Interestingly, these effects were not observed in slow-twitching soleus muscle (Derave *et al.* 2000, Wright *et al.* 2005).

AMPK regulates hepatic gluconeogenesis by inhibiting the transcription of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase; Lochhead *et al.* 2000, Cool *et al.* 2006). AMPK α 2-knockout (KO) and *LKB1*-KO mice were shown to have glucose intolerance and fasting-induced hyperglycaemia, possibly caused by increased

Figure 2 The γ -subunit of AMPK contains three AMP-binding sites. These are formed in the interface of its two pairs of CBS domains, also called Bateman domains. Two of these binding sites can bind either AMP or ATP, whereas a third site contains a tightly bound AMP that does not exchange (Xiao *et al.* 2007). When AMPK is inactive under physiological conditions, it binds two ATP and one AMP molecule, while in low energy states it binds three AMP molecules. It is now proposed that the interaction of the catalytically active kinase domain with the AMP-bound γ -subunit protects the phosphorylated Thr172 residue from dephosphorylation.

gluconeogenesis associated with increased PEPCK and G6Pase activity (Lochhead *et al.* 2000, Cool *et al.* 2006). Activated AMPK in skeletal muscle phosphorylates and inhibits glycogen synthase, thereby leading to a decrease in glycogen synthesis (Wojtaszewski *et al.* 2002).

Hypothalamic AMPK has been linked to the regulation of peripheral metabolism, suggesting that AMPK is a key enzyme in coordinating the interaction between peripheral and central energy regulation. Central AICAR treatment has been shown to increase both insulin-mediated and non-insulin-mediated glycogen synthesis (Perrin *et al.* 2004), thus implicating the role of hypothalamic AMPK in regulating muscle glycogen synthesis. Central insulin infusion also increased muscle glycogen synthesis and this effect was blocked by the co-administration of glucose, possibly mediated by AMPK (Perrin *et al.* 2004). Central adiponectin treatment leads to hypothalamic AMPK activation and decreases energy expenditure, possibly via a reduced expression of uncoupling protein-1 (UCP-1) in brown adipose tissue (Kubota *et al.* 2007). Central α -lipoic acid, which inhibits hypothalamic AMPK activity, increases UCP-1 expression and energy expenditure in brown adipose tissue (Kim *et al.* 2004b). Central ghrelin treatment, independently from the effect on food intake, has been shown to increase glucose utilisation rate of white and brown adipose tissues and counteract the effects of intracerebroventricular leptin treatment on fat weight, plasma glucose and insulin (Kim *et al.* 2004a, Theander-Carrillo *et al.* 2006).

Role of AMPK as mediator of hormonal signals

Intriguingly, several hormones have tissue-specific, often opposite, effects on AMPK activity (Fig. 3).

Leptin

Leptin increases AMPK activity in the skeletal muscle directly as well as indirectly through stimulation of the hypothalamo-sympathetic axis (Minokoshi *et al.* 2002). Chronic s.c. administration of leptin also increases the expression of AMPK in skeletal muscle (Steinberg *et al.* 2003). Leptin- or leptin receptor-deficient rodents showed a decreased AMPK activity in the liver (Yu *et al.* 2004). In lean animals, leptin has been shown to attenuate hepatic glucose production and insulin resistance under normal conditions and to slightly increase AMPK activity (Brabant *et al.* 2005). However, these effects are lost in diet-induced obese rats, thereby suggesting an important physiological dysregulation of leptin effects in obese animals. Leptin inhibits triacylglycerol storage and stimulates fatty acid oxidation in the heart, and both AMPK-dependent (Lee *et al.* 2004) and AMPK-independent (Atkinson *et al.* 2002) pathways have been suggested.

Central injection of leptin into ventromedial hypothalamus (VMH) of rats has been shown to increase glucose uptake in the heart, brown adipose tissue and skeletal muscle, but not in white adipose tissue (Kamohara

Figure 3 Hormones that activate (red) or inhibit (blue) AMPK in various tissues.

et al. 1997, Haque *et al.* 1999, Minokoshi *et al.* 1999). Central infusion of leptin decreases hepatic glycogen content (Kamohara *et al.* 1997, Haque *et al.* 1999).

In the hypothalamus, leptin has an opposite effect: it decreases AMPK activity in the ARC and paraventricular (PVC) nuclei (Minokoshi *et al.* 2002, 2004, Andersson *et al.* 2004, Mountjoy *et al.* 2007). By reducing the appetite centrally and increasing the peripheral fatty acid consumption, these tissue-specific effects of leptin lead to an overall negative energy balance and reduction in body weight.

Adiponectin

Adiponectin activates and stimulates liver and muscle AMPK activity *in vivo* and *in vitro*, leading to stimulation of glucose uptake, fatty acid oxidation and PEPCK (Yamauchi *et al.* 2002). These lead to an improvement in insulin sensitivity. Globular adiponectin was also shown to activate AMPK in primary rat adipocytes (Tomas *et al.* 2002, Yamauchi *et al.* 2002, Wu *et al.* 2003, Huypens *et al.* 2005).

Adiponectin protects the heart from ischaemic injury via AMPK- and cyclooxygenase-2-dependent mechanisms (Shibata *et al.* 2005). Adiponectin is also suggested to play a beneficial role in cardiac remodelling through multiple mechanisms, one of which is possibly via the activation of AMPK (Liao *et al.* 2005, Shibata *et al.* 2005). Impaired regulation of AMPK and glucose metabolism in adiponectin-deficient mice result in the development of heart failure (Liao *et al.* 2005). In endothelial cells, adiponectin stimulates nitric oxide production via AMPK activation, leading to beneficial vasoprotective effects (Chen *et al.* 2003).

It has been suggested that adiponectin may be involved in the stimulation of food intake (Kadowaki *et al.* 2008). Serum and cerebrospinal fluid (CSF) adiponectin concentrations increase under fasting conditions, as does expression of adiponectin receptor-1 in ARC. Central adiponectin administration leads to increased

phosphorylation of AMPK and ACC in the hypothalamus (Carling 2005, Xue & Kahn 2006, Kadowaki *et al.* 2008). Adiponectin KO mice were shown to have reduced food intake and decreased AMPK activity in ARC (Kadowaki *et al.* 2008). Thus, unlike leptin, adiponectin stimulates both central and peripheral AMPK activity. Adiponectin-transgenic ob/ob mice, which have serum adiponectin levels two- to threefold higher than ob/ob mice, have significantly higher body weight, but an improved metabolic state compared with ob/ob mice (Kim *et al.* 2007). Adiponectin is considered a starvation hormone: under fasting conditions, high adiponectin levels stimulate central and peripheral AMPK leading to increased food intake and decreased energy expenditure, promoting fat storage. After refeeding, adiponectin levels would fall with a consequent decrease in AMPK activity leading to reduced food intake and an increase in energy expenditure.

Resistin

Resistin is an adipokine secreted in rodents and humans, which generally seems to have opposite effects to those of adiponectin. Resistin induces insulin resistance and stimulates hepatic glucose production. These effects are thought to be mediated by a reduction in liver AMPK activity (Banerjee *et al.* 2004, Muse *et al.* 2004). It has been shown to decrease fatty acid uptake and oxidation in skeletal muscle via a reduction in the membrane content of fatty acid translocase/CD36, possibly mediated by inhibition of AMPK (Palanivel & Sweeney 2005). Resistin, despite its anorectic effect, has been shown to phosphorylate hypothalamic AMPK and ACC. The consequent inactivation of ACC, after AMPK activation, might represent a physiological compensatory mechanism that prevents deleteriously high levels of malonyl-CoA occurring in the hypothalamus after resistin-induced FAS inhibition in the VMH (Vazquez *et al.* 2008). Time course-dependent resistin treatments would probably be needed to clarify this issue.

Ghrelin and cannabinoids

Ghrelin has been shown to regulate AMPK activity in hypothalamus and peripheral tissues (Andersson *et al.* 2004, Kola *et al.* 2005). Cannabinoids are known to regulate appetite and peripheral metabolism, and AMPK has been shown to mediate these effects (Kola *et al.* 2005, 2008). Both ghrelin and cannabinoids have similar effects on AMPK activity in various tissues: they stimulate hypothalamic and heart AMPK activity, while inhibit adipose tissue and liver AMPK activity (Kola *et al.* 2005, 2008).

The mechanism of central effect of ghrelin includes the activation of Ca^{2+} signalling in NPY neurons in the ARC (Kohnno *et al.* 2003, 2008). The Ca^{2+} rise leads to CAMKK2 activation, which can stimulate hypothalamic AMPK (Anderson *et al.* 2008, Sleeman & Latres 2008). AMPK activation leads to inhibition of malonyl-CoA and stimulation of CPT1, leading to increased mitochondrial oxidation and activation of the UCP-2, which can increase NPY/AgRP neuronal activity and ultimately stimulate appetite (Andrews *et al.* 2008, Lopez *et al.* 2008).

Endocannabinoids are synthesised locally on demand, and the level in the hypothalamus varies in response to feeding and fasting (Kirkham *et al.* 2002). The variation in hypothalamic endocannabinoid levels seems to play an important role in mediating the anorectic effects of leptin (Di Marzo *et al.* 2001) and the orexigenic effects of ghrelin (Kola *et al.* 2008). Recently, we have shown that the effects of ghrelin on hypothalamic AMPK activity and appetite are abolished in the absence of cannabinoid type 1 receptor (CB1) or in the presence of a CB1 antagonist rimonabant (Kola *et al.* 2008). These data suggest that an intact cannabinoid-signalling pathway is required for the effects of ghrelin on AMPK activity and appetite. Interestingly, i.p. injection of cannabinoids in rats results in increased plasma ghrelin levels (Zbucki *et al.* 2008). This suggests that the stimulation of appetite by cannabinoids may be connected to an increase in ghrelin secretion from the gastric X/A-like cells (Zbucki *et al.* 2008). Further studies are needed to elucidate the details of the ghrelin–cannabinoid interaction.

Insulin

Insulin has a range of metabolic effects in addition to its main role of stimulating glucose uptake into the cells. Centrally, insulin is an anorectic hormone, which has been shown to inhibit hypothalamic AMPK activity (Minokoshi *et al.* 2004). Insulin deficiency has been proposed as one of the factors causing hypothalamic AMPK activation and the subsequent increase in food intake seen in streptozotocin-induced diabetic rats (Namkoong *et al.* 2005). In the periphery, insulin inhibits AMPK in fat by activating protein kinase B/Akt

complex, which can phosphorylate alphaAMPK at Ser485/491, thus leading to reduced phosphorylation at Thr172 (Kovacic *et al.* 2003, Horman *et al.* 2006). Insulin inhibits myocardial AMPK activity during ischaemic events alone or when co-administered with glucose, suggesting that the inhibitory effect of insulin on myocardial AMPK activity might be caused by enhanced glucose metabolism (Russell *et al.* 2004).

Insulin resistance is characterised by the inability of insulin to increase glucose uptake and repress glucose production in the liver, and it often leads to hyperglycaemia. The role of AMPK in this condition has to be considered. While activated AMPK stimulates catabolic pathways and inhibits the energy-consuming anabolic processes, insulin promotes glycogen, lipid and protein synthesis. However, both upregulate glucose uptake in muscle via an effect of GLUT1 or GLUT4 translocation and increase in GLUT4 transcription (Zheng *et al.* 2001, Barnes *et al.* 2002). In skeletal muscle, the two pathways also phosphorylate the protein AS160, which has a Rab GTPase-activating protein domain that can increase translocation of GLUT4 to the plasma membrane (Kurth-Kraczek *et al.* 1999, Kramer *et al.* 2006, Treebak *et al.* 2006). These factors will lead to an increase in glucose uptake, which is an important homeostatic feature of plasma glucose regulation. Furthermore, AMPK activation is thought to upregulate insulin receptor substrate-1 (Harrington *et al.* 2004, Shah *et al.* 2004, Um *et al.* 2004) through inhibition of the insulin–mammalian target of rapamycin (mTOR) pathway (Fisher *et al.* 2002, Inoki *et al.* 2003). This will improve the insulin sensitivity profile. Both insulin and activated AMPK repress the expression of the gluconeogenic enzymes PEPCK and G6Pase (Lochhead *et al.* 2000). Phosphorylation of AMPK is thought to result in translocation of the transcriptional coactivator TORC2 to the cytoplasm (Koo *et al.* 2005), thus repressing the expression of the TORC2-target enzymes

Glucagon-like peptide-1

GLP-1 is produced from pre-proglucagon mRNA, which is expressed in NTS cell bodies in the brainstem, with projections to the PVN and other hypothalamic nuclei involved in the control of feeding (Goldstone *et al.* 2000). Central nervous system GLP-1 is an endogenous inhibitor of feeding acting via the GLP-1 receptor. Hypothalamic GLP-1 peptide content is decreased during fasting. Fasting-induced increase in hypothalamic AMPK activity is inhibited by GLP-1 and this could be the mechanism of its anorectic effects (Seo *et al.* 2008). It has been shown that the anorectic effects of leptin are at least partly via GLP-1. GLP-1 acts in both the hypothalamus and the NTS, as GLP-1 receptors located in the NTS are also suggested to regulate food intake (Hayes *et al.* 2009b).

Glucocorticoids

Glucocorticoids increase appetite and lead to increased availability of metabolic fuels such as amino acids and fatty acids. Chronic or excessive exposure to glucocorticoids will result in insulin resistance, truncal obesity, hyperlipidaemia and symptoms similar to the metabolic syndrome. We have suggested that AMPK is involved in the central and peripheral effects of glucocorticoids. Glucocorticoids activate hypothalamic AMPK activity *in vivo* (Christ-Crain *et al.* 2008) either directly or via stimulation of endocannabinoid synthesis (Di *et al.* 2005, Christ-Crain *et al.* 2008), and these effects could lead to appetite stimulation (Tataranni *et al.* 1996). In the periphery, glucocorticoids inhibit AMPK activity in adipose tissue, leading to increased lipogenesis and fat storage (Christ-Crain *et al.* 2008). Glucocorticoids also inhibited AMPK activity in the heart, which might, at least in part, mediate the detrimental effects of glucocorticoid excess on the heart. Surprisingly, and somewhat unexpectedly, glucocorticoids were shown to stimulate AMPK activity in rat liver *in vivo* as well as in a liver cell line (Viana *et al.* 2006, Christ-Crain *et al.* 2008). This could be the result of the balance of local lipolysis, lipid oxidation and the flux of fatty acids into the liver (Foretz *et al.* 2005). It has been shown that an increase in free fatty acids leads to fatty acid esterification, an energy-demanding process, and this can increase the cellular AMP:ATP ratio and therefore AMPK activity (Gauthier *et al.* 2008).

Inflammatory mediators and AMPK

Interleukin-6 (IL-6) treatment was shown to increase AMPK phosphorylation in cultured rodent myocytes and adipocytes, as well as in muscle, liver and adipose tissue *in vivo* (Keller *et al.* 2001, Park *et al.* 2002, Kahn *et al.* 2005). Moreover, IL-6-KO mice have decreased AMPK activity in muscle (Kelly *et al.* 2004). Conversely, adiponectin was shown to increase IL-6 production in human synovial fibroblasts partly via AMPK regulation (Tang *et al.* 2007). Exercise increases AMPK activity in skeletal muscle primarily in response to changes in the AMP:ATP ratio (Ruderman *et al.* 2006). Exercise affects AMPK activity in fat and liver tissue (Takekoshi *et al.* 2006) possibly due to an increase in circulating levels of IL-6 (Keller *et al.* 2001). Furthermore, AMPK activity is often still increased after exercise at times when the energy state of the muscle is presumably no longer altered, and IL-6 is suggested to be involved in AMPK activation during this 'late-phase' stage (Ruderman *et al.* 2006).

Ciliary neurotrophic factor (CNTF) is a cytokine, which was found to induce severe anorectic effect (Miller *et al.* 1996), possibly via hypothalamic neurogenesis that

leads to sustained reduction in caloric intake and prolonged maintenance of weight loss (Kokoeva *et al.* 2005). CNTF was shown to activate AMPK through the CNTFR α -IL-6R-gp130 β receptor complex and ultimately increasing fatty acid oxidation and reducing insulin resistance in skeletal muscle (Steinberg *et al.* 2006b). CNTF can also suppress inflammatory signalling cascades associated with lipid accumulation in the liver and skeletal muscle (Febbraio 2007).

The ischaemic heart releases macrophage inhibitory factor (MIF), an upstream regulator of inflammation. MIF stimulates AMPK through CD74 during ischaemia, and shows impaired ischaemic AMPK signalling in the heart of mice with germline deletion of the *MIF* gene (Miller *et al.* 2008). MIF promotes glucose uptake and protects the heart during ischaemia-reperfusion injury (Miller *et al.* 2008). Human fibroblasts with a low-activity MIF promoter polymorphism also have diminished MIF release and AMPK activation during hypoxia, thus linking inflammation with metabolism in the heart (Miller *et al.* 2008).

Tumour necrosis factor α (TNF α) signalling via TNF-receptor has been shown to suppress skeletal muscle AMPK activity both *in vivo* and *in vitro* (Steinberg *et al.* 2006a). This happens via upregulation of protein phosphatase 2C transcription, which in turn reduces ACC phosphorylation and fatty acid oxidation as well as increasing diacylglycerol accumulation in the muscle. Suppressing effects of TNF α on AMPK activity, seen in obese mice with pathologically elevated levels of TNF α , could be reversed in null mice for both TNF receptor-1 and -2 or following treatment with a TNF α -neutralising antibody (Steinberg *et al.* 2006a). This indicates that AMPK is an important target for TNF α signalling.

Metabolic syndrome and AMPK

The metabolic abnormalities observed in metabolic syndrome are insulin resistance, hypertriglyceridaemia, abdominal obesity, hypertension, reduced levels of the beneficial high-density lipoprotein and disturbances in glucose metabolism (Trevisan *et al.* 1998). Patients with metabolic syndrome have higher risks of developing cardiovascular disease (Isomaa *et al.* 2001) and have higher rates of mortality from all causes (Trevisan *et al.* 1998). Downstream targets of AMPK such as genes regulating carbohydrate metabolism (e.g. glycogen synthetase, ChREBP) or lipid metabolism (e.g. HMG-CoA, FAS, ACC, SREBP1) play an important role in features of the metabolic syndrome. Therefore, AMPK emerged as a target for treatment of the metabolic syndrome. Two major anti-diabetic drugs that exert effects via the AMPK pathway will be considered in this review: metformin and rosiglitazone.

Metformin

Metformin, a biguanide agent, is widely used as an anti-diabetic drug. The biguanide class of anti-diabetic drugs originates from the French lilac (*Galega officinalis*) plant, known for several centuries to reduce the symptoms of diabetes mellitus (Witters 2001). These were first introduced in 1957 and marketed in France in 1979.

Metformin is shown to stimulate AMPK in the liver and in the muscle (Zhou *et al.* 2001, Zang *et al.* 2004, Shaw *et al.* 2005). This consequently stimulates glucose uptake in the muscle, induces hepatic fatty acid oxidation and inhibits hepatic glucose production and expression of lipogenic enzymes. Metformin does not activate AMPK directly, but indirectly via inhibition of complex I of the respiratory chain and the consequent increase in AMP:ATP ratio. LKB1 has also been reported to mediate the activation of AMPK in the liver by metformin (Zhou *et al.* 2001, Zang *et al.* 2004, Shaw *et al.* 2005).

In contrast, metformin inhibits AMPK in the hypothalamus (Chau-Van *et al.* 2007). Metformin inhibits low glucose-induced AMPK phosphorylation and NPY mRNA expression. These may explain the anorectic effects of metformin.

Metformin is shown to reduce mitochondrial ATP synthesis in the pancreatic β -cell, resulting in impaired glucose responsiveness, inhibition of insulin release and possibly apoptosis (Kefas *et al.* 2004, Leclerc *et al.* 2004). These findings of metformin are clearly undesired and further studies are needed to reassess the long-term effects of metformin on β -cells.

Rosiglitazone

Rosiglitazone belongs to a class of anti-diabetic drugs known as thiazolidinediones (TZDs). TZDs are used to reverse insulin resistance and improve glucose tolerance. It is known that TZDs improve insulin sensitivity by activating nuclear PPAR- γ and the consequent regulation of gene transcription. However, it is also believed that TZDs can improve insulin sensitivity via PPAR- γ -independent mechanisms, one of which is AMPK activation (Kahn *et al.* 2005).

Rosiglitazone was shown to increase AMPK activity in muscle cell lines (Fryer *et al.* 2002), and chronic rosiglitazone treatment was reported to restore skeletal muscle AMPK α 2 activity in obese, insulin-resistant Zucker rats (Lessard *et al.* 2006). Rosiglitazone activates AMPK indirectly by inhibiting complex I of the respiratory chain, which consequently leads to an increase in cellular AMP:ATP ratio (El-Mir *et al.* 2000, Owen *et al.* 2000, Brunmair *et al.* 2004).

TZDs also decrease the levels of resistin and stimulate release of adiponectin via action on PPAR- γ in adipocytes (Samaha *et al.* 2006). These effects might also contribute to the stimulatory effect of TZDs on AMPK.

Conclusion

AMPK is one of the key regulators in energy homeostasis and is known to mediate the effects of several metabolic hormones. AMPK is now recognised as a potential target for the treatment of obesity and the metabolic syndrome.

Declaration of interest

The authors have nothing to declare.

Funding

C T Lim was supported by a Wellcome Trust Summer Studentship, and B Kola and M Korbonits are supported by a Wellcome Trust Research Grant.

Acknowledgements

We are very grateful to Dr Steve Gamblin (MRC, London) for the helpful comments on the structural description of AMPK activation.

References

- Anderson KA, Ribar TJ, Lin F, Noeldner PK, Green MF, Muehlbauer MJ, Witters LA, Kemp BE & Means AR 2008 Hypothalamic CaMKK2 contributes to the regulation of energy balance. *Cell Metabolism* **7** 377–388.
- Andersson U, Filipsson K, Abbott CR, Woods A, Smith K, Bloom SR, Carling D & Small CJ 2004 AMP-activated protein kinase plays a role in the control of food intake. *Journal of Biological Chemistry* **279** 12005–12008.
- Andrews ZB, Liu ZW, Wallingford N, Erion DM, Borok E, Friedman JM, Tschop MH, Shanabrough M, Cline G, Shulman GI *et al.* 2008 UCP-2 mediates ghrelin's action on NPY/AgRP neurons by lowering free radicals. *Nature* **454** 846–851.
- Atkinson LL, Fischer MA & Lopaschuk GD 2002 Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl-CoA axis. *Journal of Biological Chemistry* **277** 29424–29430.
- Banerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, Qi Y, Wang J, Rajala MW, Pocai A, Scherer PE *et al.* 2004 Regulation of fasted blood glucose by resistin. *Science* **303** 1195–1198.
- Barnes K, Ingram JC, Porras OH, Barros LF, Hudson ER, Fryer LG, Foulfelle F, Carling D, Hardie DG & Baldwin SA 2002 Activation of GLUT1 by metabolic and osmotic stress: potential involvement of AMP-activated protein kinase (AMPK). *Journal of Cell Science* **115** 2433–2442.
- Beg ZH, Allmann DW & Gibson DM 1973 Modulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity with cAMP and with protein fractions of rat liver cytosol. *Biochemical and Biophysical Research Communications* **54** 1362–1369.
- Brabant G, Muller G, Horn R, Anderwald C, Roden M & Nave H 2005 Hepatic leptin signaling in obesity. *FASEB Journal* **19** 1048–1050.
- Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, Roden M, Gnaiger E, Nohl H, Waldhausl W *et al.* 2004 Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? *Diabetes* **53** 1052–1059.
- Carling D 2005 AMP-activated protein kinase: balancing the scales. *Biochimie* **87** 87–91.
- Carling D 2009 Branching out on AMPK regulation. *Cell Metabolism* **9** 7–8.

- Carlson CA & Kim KH 1973 Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation. *Journal of Biological Chemistry* **248** 378–380.
- Chau-Van C, Gamba M, Salvi R, Gaillard RC & Pralong FP 2007 Metformin inhibits adenosine 5'-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons. *Endocrinology* **148** 507–511.
- Chen H, Montagnani M, Funahashi T, Shimomura I & Quon MJ 2003 Adiponectin stimulates production of nitric oxide in vascular endothelial cells. *Journal of Biological Chemistry* **278** 45021–45026.
- Christ-Crain M, Kola B, Lolli F, Fekete C, Seboek D, Wittmann G, Feltrin D, Igreja SC, Ajodha S, Harvey-White J *et al.* 2008 AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. *FASEB Journal* **22** 1672–1683.
- Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M, Dickinson R, Adler A, Gagne G, Iyengar R *et al.* 2006 Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. *Cell Metabolism* **3** 403–416.
- Corton JM, Gillespie JG, Hawley SA & Hardie DG 1995 5-Aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? *European Journal of Biochemistry* **229** 558–565.
- Date Y, Shimbara T, Koda S, Toshinai K, Ida T, Murakami N, Miyazato M, Kokame K, Ishizuka Y, Ishida Y *et al.* 2006 Peripheral ghrelin transmits orexigenic signals through the noradrenergic pathway from the hindbrain to the hypothalamus. *Cell Metabolism* **4** 323–331.
- Daval M, Diot-Dupuy F, Bazin R, Hainault I, Viollet B, Vaulont S, Hajdich E, Ferre P & Foulfelle F 2005 Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes. *Journal of Biological Chemistry* **280** 25250–25257.
- Derave W, Ai H, Ihlemann J, Witters LA, Kristiansen S, Richter EA & Ploug T 2000 Dissociation of AMP-activated protein kinase activation and glucose transport in contracting slow-twitch muscle. *Diabetes* **49** 1281–1287.
- Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T *et al.* 2001 Leptin-regulated endocannabinoids are involved in maintaining food intake. *Nature* **410** 822–825.
- Di S, Malcher-Lopes R, Marcheselli VL, Bazan NG & Tasker JG 2005 Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and gamma-aminobutyric acid inputs to hypothalamic magnocellular neurons. *Endocrinology* **146** 4292–4301.
- Divertie GD, Jensen MD & Miles JM 1991 Stimulation of lipolysis in humans by physiological hypercortisolemia. *Diabetes* **40** 1228–1232.
- Djurhuus CB, Gravholt CH, Nielsen S, Mengel A, Christiansen JS, Schmitz OE & Moller N 2002 Effects of cortisol on lipolysis and regional interstitial glycerol levels in humans. *American Journal of Physiology. Endocrinology and Metabolism* **283** E172–E177.
- El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M & Leverve X 2000 Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. *Journal of Biological Chemistry* **275** 223–228.
- Febbraio MA 2007 gp130 receptor ligands as potential therapeutic targets for obesity. *Journal of Clinical Investigation* **117** 841–849.
- Fisher JS, Gao J, Han DH, Holloszy JO & Nolte LA 2002 Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. *American Journal of Physiology. Endocrinology and Metabolism* **282** E18–E23.
- Foretz M, Ancellin N, Andreelli F, Saintillan Y, Grondin P, Kahn A, Thorens B, Vaulont S & Viollet B 2005 Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. *Diabetes* **54** 1331–1339.
- Fryer LG, Parbu-Patel A & Carling D 2002 The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. *Journal of Biological Chemistry* **277** 25226–25232.
- Fu X, Wan S, Lyu YL, Liu LF & Qi H 2008 Etoposide induces ATM-dependent mitochondrial biogenesis through AMPK activation. *PLoS ONE* **3** e2008.
- Gauthier MS, Miyoshi H, Souza SC, Cacicedo JM, Saha AK, Greenberg AS & Ruderman NB 2008 AMP-activated protein kinase is activated as a consequence of lipolysis in the adipocyte: potential mechanism and physiological relevance. *Journal of Biological Chemistry* **283** 16514–16524.
- Goldstone AP, Morgan I, Mercer JG, Morgan DG, Moar KM, Ghatei MA & Bloom SR 2000 Effect of leptin on hypothalamic GLP-1 peptide and brain-stem pre-proglucagon mRNA. *Biochemical and Biophysical Research Communications* **269** 331–335.
- Haque MS, Minokoshi Y, Hamai M, Iwai M, Horiuchi M & Shimazu T 1999 Role of the sympathetic nervous system and insulin in enhancing glucose uptake in peripheral tissues after intrahypothalamic injection of leptin in rats. *Diabetes* **48** 1706–1712.
- Hardie DG, Salt IP, Hawley SA & Davies SP 1999 AMP-activated protein kinase: an ultrasensitive system for monitoring cellular energy charge. *Biochemical Journal* **338** 717–722.
- Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR *et al.* 2004 The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. *Journal of Cell Biology* **166** 213–223.
- Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, Alessi DR & Hardie DG 2003 Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. *Journal of Biology* **2** 28.
- Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, Edelman AM, Frenguelli BG & Hardie DG 2005 Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. *Cell Metabolism* **2** 9–19.
- Hayes MR, Bradley L & Grill HJ 2009a Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling. *Endocrinology* **150** 2654–2659.
- Hayes MR, Skibicka KP, Bence KK & Grill HJ 2009b Dorsal hindbrain 5'-adenosine monophosphate-activated protein kinase as an intracellular mediator of energy balance. *Endocrinology* **150** 2175–2182.
- Holmes BF, Kurth-Kraczek EJ & Winder WW 1999 Chronic activation of 5'-AMP-activated protein kinase increases GLUT4, hexokinase, and glycogen in muscle. *Journal of Applied Physiology* **87** 1990–1995.
- Horman S, Vertommen D, Heath R, Neumann D, Mouton V, Woods A, Schlattner U, Wallimann T, Carling D, Hue L *et al.* 2006 Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser485/491. *Journal of Biological Chemistry* **281** 5335–5340.
- Hurley RL, Anderson KA, Franzoni JM, Kemp BE, Means AR & Witters LA 2005 The Ca²⁺/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. *Journal of Biological Chemistry* **280** 29060–29066.
- Huypens P, Moens K, Heimberg H, Ling Z, Pipeleers D & Van de Casteele M 2005 Adiponectin-mediated stimulation of AMP-activated protein kinase (AMPK) in pancreatic beta cells. *Life Sciences* **77** 1273–1282.
- Inoki K, Zhu T & Guan KL 2003 TSC2 mediates cellular energy response to control cell growth and survival. *Cell* **115** 577–590.
- Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR & Groop L 2001 Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care* **24** 683–689.

- Kadowaki T, Yamauchi T & Kubota N 2008 The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. *FEBS Letters* **582** 74–80.
- Kahn BB, Alquier T, Carling D & Hardie DG 2005 AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. *Cell Metabolism* **1** 15–25.
- Kamohara S, Burcelin R, Halaas JL, Friedman JM & Charron MJ 1997 Acute stimulation of glucose metabolism in mice by leptin treatment. *Nature* **389** 374–377.
- Kefas BA, Cai Y, Kerckhofs K, Ling Z, Martens G, Heimberg H, Pipeleers D & Van de Castele M 2004 Metformin-induced stimulation of AMP-activated protein kinase in beta-cells impairs their glucose responsiveness and can lead to apoptosis. *Biochemical Pharmacology* **68** 409–416.
- Keller C, Steensberg A, Pilegaard H, Osada T, Saltin B, Pedersen BK & Neufer PD 2001 Transcriptional activation of the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content. *FASEB Journal* **15** 2748–2750.
- Kelly M, Keller C, Avilucea PR, Keller P, Luo Z, Xiang X, Giralt M, Hidalgo J, Saha AK, Pedersen BK *et al.* 2004 AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. *Biochemical and Biophysical Research Communications* **320** 449–454.
- Kim MS, Namkoong C, Kim HS, Jang PG, Kim Pak YM, Katakami H, Park JY & Lee KU 2004a Chronic central administration of ghrelin reverses the effects of leptin. *International Journal of Obesity and Related Metabolic Disorders* **28** 1264–1271.
- Kim MS, Park JY, Namkoong C, Jang PG, Ryu JW, Song HS, Yun JY, Namgoong IS, Ha J, Park IS *et al.* 2004b Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. *Nature Medicine* **10** 727–733.
- Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, Schraw T, Durand JL, Li H, Li G *et al.* 2007 Obesity-associated improvements in metabolic profile through expansion of adipose tissue. *Journal of Clinical Investigation* **117** 2621–2637.
- Kirkham TC, Williams CM, Fezza F & Di Marzo V 2002 Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiety: stimulation of eating by 2-arachidonoyl glycerol. *British Journal of Pharmacology* **136** 550–557.
- Kohn D, Gao HZ, Muroya S, Kikuyama S & Yada T 2003 Ghrelin directly interacts with neuropeptide-Y-containing neurons in the rat arcuate nucleus: Ca^{2+} signaling via protein kinase A and N-type channel-dependent mechanisms and cross-talk with leptin and orexin. *Diabetes* **52** 948–956.
- Kohn D, Sone H, Minokoshi Y & Yada T 2008 Ghrelin raises $[Ca^{2+}]_i$ via AMPK in hypothalamic arcuate nucleus NPY neurons. *Biochemical and Biophysical Research Communications* **366** 388–392.
- Kokoeva MV, Yin H & Flier JS 2005 Neurogenesis in the hypothalamus of adult mice: potential role in energy balance. *Science* **310** 679–683.
- Kola B 2008 Role of AMP-activated protein kinase in the control of appetite. *Journal of Neuroendocrinology* **20** 942–951.
- Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, Mitchell SE, Williams LM, Hawley SA, Hardie DG, Grossman AB *et al.* 2005 Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. *Journal of Biological Chemistry* **280** 25196–25201.
- Kola B, Farkas I, Christ-Crain M, Wittmann G, Lolli F, Amin F, Harvey-White J, Liposits Z, Kunos G, Grossman AB *et al.* 2008 The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. *PLoS ONE* **3** e1797.
- Koo SH, Flechner L, Qi L, Zhang X, Sreaton RA, Jeffries S, Hedrick S, Xu W, Boussouar F, Brindle P *et al.* 2005 The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. *Nature* **437** 1109–1111.
- Kovacic S, Soltys CL, Barr AJ, Shiojima I, Walsh K & Dyck JR 2003 Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. *Journal of Biological Chemistry* **278** 39422–39427.
- Kramer HF, Witczak CA, Fujii N, Jessen N, Taylor EB, Arnolds DE, Sakamoto K, Hirshman MF & Goodyear LJ 2006 Distinct signals regulate AS160 phosphorylation in response to insulin, AICAR, and contraction in mouse skeletal muscle. *Diabetes* **55** 2067–2076.
- Kubota N, Yano W, Kubota T, Yamauchi T, Itoh S, Kumagai H, Kozono H, Takamoto I, Okamoto S, Shiuchi T *et al.* 2007 Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. *Cell Metabolism* **6** 55–68.
- Kurth-Kraczek EJ, Hirshman MF, Goodyear LJ & Winder WW 1999 5' AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. *Diabetes* **48** 1667–1671.
- Leclerc I, Woltersdorf WW, da Silva Xavier G, Rowe RL, Cross SE, Korbitt GS, Rajotte RV, Smith R & Rutter GA 2004 Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. *American Journal of Physiology. Endocrinology and Metabolism* **286** E1023–E1031.
- Lee Y, Naseem RH, Duplomb L, Park BH, Garry DJ, Richardson JA, Schaffer JE & Unger RH 2004 Hyperleptinemia prevents lipotoxic cardiomyopathy in acyl CoA synthase transgenic mice. *PNAS* **101** 13624–13629.
- Lessard SJ, Chen ZP, Watt MJ, Hashem M, Reid JJ, Febbraio MA, Kemp BE & Hawley JA 2006 Chronic rosiglitazone treatment restores AMPK α 2 activity in insulin-resistant rat skeletal muscle. *American Journal of Physiology. Endocrinology and Metabolism* **290** E251–E257.
- Liao Y, Takashima S, Maeda N, Ouchi N, Komamura K, Shimomura I, Hori M, Matsuzawa Y, Funahashi T & Kitakaze M 2005 Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. *Cardiovascular Research* **67** 705–713.
- Lochhead PA, Salt IP, Walker KS, Hardie DG & Sutherland C 2000 5-Aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. *Diabetes* **49** 896–903.
- Lopez M, Lelliott CJ & Vidal-Puig A 2007 Hypothalamic fatty acid metabolism: a housekeeping pathway that regulates food intake. *BioEssays* **29** 248–261.
- Lopez M, Lage R, Saha AK, Perez-Tilve D, Vazquez MJ, Varela L, Sangiao-Alvarellos S, Tovar S, Raghu K, Rodriguez-Cuenca S *et al.* 2008 Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. *Cell Metabolism* **7** 389–399.
- McBride A, Ghilagaber S, Nikolaev A & Hardie DG 2009 The glycogen-binding domain on the AMPK beta subunit allows the kinase to act as a glycogen sensor. *Cell Metabolism* **9** 23–34.
- Merrill GF, Kurth EJ, Hardie DG & Winder WW 1997 AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. *American Journal of Physiology* **273** E1107–E1112.
- Miller RG, Petajan JH, Bryan WW, Armon C, Barohn RJ, Goodpasture JC, Hoagland RJ, Parry GJ, Ross MA & Stromatt SC 1996 A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. *Annals of Neurology* **39** 256–260.
- Miller EJ, Li J, Leng L, McDonald C, Atsumi T, Bucala R & Young LH 2008 Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. *Nature* **451** 578–582.
- Minokoshi Y, Haque MS & Shimazu T 1999 Microinjection of leptin into the ventromedial hypothalamus increases glucose uptake in peripheral tissues in rats. *Diabetes* **48** 287–291.
- Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D & Kahn BB 2002 Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. *Nature* **415** 339–343.
- Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, Mu J, Foufelle F, Ferre P, Birnbaum MJ *et al.* 2004 AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. *Nature* **428** 569–574.

- Momcilovic M, Hong SP & Carlson M 2006 Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase *in vitro*. *Journal of Biological Chemistry* **281** 25336–25343.
- Mountjoy PD, Bailey SJ & Rutter GA 2007 Inhibition by glucose or leptin of hypothalamic neurons expressing neuropeptide Y requires changes in AMP-activated protein kinase activity. *Diabetologia* **50** 168–177.
- Muse ED, Obici S, Bhanot S, Monia BP, McKay RA, Rajala MW, Scherer PE & Rossetti L 2004 Role of resistin in diet-induced hepatic insulin resistance. *Journal of Clinical Investigation* **114** 232–239.
- Namkoong C, Kim MS, Jang PG, Han SM, Park HS, Koh EH, Lee WJ, Kim JY, Park IS, Park JY *et al.* 2005 Enhanced hypothalamic AMP-activated protein kinase activity contributes to hyperphagia in diabetic rats. *Diabetes* **54** 63–68.
- Owen MR, Doran E & Halestrap AP 2000 Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. *Biochemical Journal* **348** 607–614.
- Palanivel R & Sweeney G 2005 Regulation of fatty acid uptake and metabolism in L6 skeletal muscle cells by resistin. *FEBS Letters* **579** 5049–5054.
- Park H, Kaushik VK, Constant S, Prentki M, Przybytkowski E, Ruderman NB & Saha AK 2002 Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. *Journal of Biological Chemistry* **277** 32571–32577.
- Perrin C, Knauf C & Burcelin R 2004 Intracerebroventricular infusion of glucose, insulin, and the adenosine monophosphate-activated kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside, controls muscle glycogen synthesis. *Endocrinology* **145** 4025–4033.
- Qi J, Gong J, Zhao T, Zhao J, Lam P, Ye J, Li JZ, Wu J, Zhou HM & Li P 2008 Downregulation of AMP-activated protein kinase by Cidea-mediated ubiquitination and degradation in brown adipose tissue. *EMBO Journal* **27** 1537–1548.
- Ruderman NB, Keller C, Richard AM, Saha AK, Luo Z, Xiang X, Giral M, Ritov VB, Menshikova EV, Kelley DE *et al.* 2006 Interleukin-6 regulation of AMP-activated protein kinase. Potential role in the systemic response to exercise and prevention of the metabolic syndrome. *Diabetes* **55** S48–S54.
- Russell RR III, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, Giordano FJ, Mu J, Birnbaum MJ & Young LH 2004 AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. *Journal of Clinical Investigation* **114** 495–503.
- Samaha FF, Szapary PO, Iqbal N, Williams MM, Bloedon LT, Kochar A, Wolfe ML & Rader DJ 2006 Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. *Arteriosclerosis, Thrombosis, and Vascular Biology* **26** 624–630.
- Sanders MJ, Grondin PO, Hegarty BD, Snowden MA & Carling D 2007 Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. *Biochemical Journal* **403** 139–148.
- Seo S, Ju S, Chung H, Lee D & Park S 2008 Acute effects of glucagon-like peptide-1 on hypothalamic neuropeptide and AMP activated kinase expression in fasted rats. *Endocrine Journal* **55** 867–874.
- Shah OJ, Wang Z & Hunter T 2004 Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. *Current Biology* **14** 1650–1656.
- Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA & Cantley LC 2004 The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. *PNAS* **101** 3329–3335.
- Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M & Cantley LC 2005 The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. *Science* **310** 1642–1646.
- Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi T, Ouchi N & Walsh K 2005 Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. *Nature Medicine* **11** 1096–1103.
- Sleeman MW & Latres E 2008 The CAMplexities of central ghrelin. *Cell Metabolism* **7** 361–362.
- Steinberg GR, Rush JW & Dyck DJ 2003 AMPK expression and phosphorylation are increased in rodent muscle after chronic leptin treatment. *American Journal of Physiology. Endocrinology and Metabolism* **284** E648–E654.
- Steinberg GR, Michell BJ, van Denderen BJ, Watt MJ, Carey AL, Fam BC, Andrikopoulos S, Proietto J, Gorgun CZ, Carling D *et al.* 2006a Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. *Cell Metabolism* **4** 465–474.
- Steinberg GR, Watt MJ, Fam BC, Proietto J, Andrikopoulos S, Allen AM, Febbraio MA & Kemp BE 2006b Ciliary neurotrophic factor suppresses hypothalamic AMP-kinase signaling in leptin-resistant obese mice. *Endocrinology* **147** 3906–3914.
- Takekoshi K, Fukuhara M, Quin Z, Nissato S, Isobe K, Kawakami Y & Ohmori H 2006 Long-term exercise stimulates adenosine monophosphate-activated protein kinase activity and subunit expression in rat visceral adipose tissue and liver. *Metabolism* **55** 1122–1128.
- Tang CH, Chiu YC, Tan TW, Yang RS & Fu WM 2007 Adiponectin enhances IL-6 production in human synovial fibroblast via an AdipoR1 receptor, AMPK, p38, and NF-kappa B pathway. *Journal of Immunology* **179** 5483–5492.
- Tataranni PA, Larson DE, Snitker S, Young JB, Flatt JP & Ravussin E 1996 Effects of glucocorticoids on energy metabolism and food intake in humans. *American Journal of Physiology* **271** E317–E325.
- Terada S, Goto M, Kato M, Kawanaka K, Shimokawa T & Tabata I 2002 Effects of low-intensity prolonged exercise on PGC-1 mRNA expression in rat epitrochlear muscle. *Biochemical and Biophysical Research Communications* **296** 350–354.
- Theander-Carrillo C, Wiedmer P, Cettour-Rose P, Nogueiras R, Perez-Tilve D, Pfluger P, Castaneda TR, Muzzin P, Schurmann A, Szanto I *et al.* 2006 Ghrelin action in the brain controls adipocyte metabolism. *Journal of Clinical Investigation* **116** 1983–1993.
- Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang CC, Itani SI, Lodish HF & Ruderman NB 2002 Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. *PNAS* **99** 16309–16313.
- Towler MC & Hardie DG 2007 AMP-activated protein kinase in metabolic control and insulin signaling. *Circulation Research* **100** 328–341.
- Trebbak JT, Glund S, Deshmukh A, Klein DK, Long YC, Jensen TE, Jorgensen SB, Viollet B, Andersson L, Neumann D *et al.* 2006 AMPK-mediated AS160 phosphorylation in skeletal muscle is dependent on AMPK catalytic and regulatory subunits. *Diabetes* **55** 2051–2058.
- Trévisan M, Liu J, Bahsas FB & Menotti A 1998 Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. *American Journal of Epidemiology* **148** 958–966.
- Turnley AM, Stapleton D, Mann RJ, Witters LA, Kemp BE & Bartlett PF 1999 Cellular distribution and developmental expression of AMP-activated protein kinase isoforms in mouse central nervous system. *Journal of Neurochemistry* **72** 1707–1716.
- Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J *et al.* 2004 Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. *Nature* **431** 200–205.

- Vazquez MJ, Gonzalez CR, Varela L, Lage R, Tovar S, Sangiao-Alvarellos S, Williams LM, Vidal-Puig A, Nogueiras R, Lopez M *et al.* 2008 Central resistin regulates hypothalamic and peripheral lipid metabolism in a nutritional-dependent fashion. *Endocrinology* **149** 4534–4543.
- Viana AY, Sakoda H, Anai M, Fujishiro M, Ono H, Kushiya A, Fukushima Y, Sato Y, Oshida Y, Uchijima Y *et al.* 2006 Role of hepatic AMPK activation in glucose metabolism and dexamethasone-induced regulation of AMPK expression. *Diabetes Research and Clinical Practice* **73** 135–142.
- Witters LA 2001 The blooming of the French lilac. *Journal of Clinical Investigation* **108** 1105–1107.
- Wojtaszewski JF, Jorgensen SB, Hellsten Y, Hardie DG & Richter EA 2002 Glycogen-dependent effects of 5-aminoimidazole-4-carboxamide (AICA)-riboside on AMP-activated protein kinase and glycogen synthase activities in rat skeletal muscle. *Diabetes* **51** 284–292.
- Woods A, Azzout-Marniche D, Foretz M, Stein SC, Lemarchand P, Ferre P, Foufelle F & Carling D 2000 Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. *Molecular and Cellular Biology* **20** 6704–6711.
- Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, Schlattner U, Wallimann T, Carlson M & Carling D 2003 LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. *Current Biology* **13** 2004–2008.
- Woods A, Dickerson K, Heath R, Hong SP, Momcilovic M, Johnstone SR, Carlson M & Carling D 2005 Ca^{2+} /calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. *Cell Metabolism* **2** 21–33.
- Wright DC, Geiger PC, Holloszy JO & Han DH 2005 Contraction- and hypoxia-stimulated glucose transport is mediated by a Ca^{2+} -dependent mechanism in slow-twitch rat soleus muscle. *American Journal of Physiology. Endocrinology and Metabolism* **288** E1062–E1066.
- Wu X, Motoshima H, Mahadev K, Stalker TJ, Scalia R & Goldstein BJ 2003 Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. *Diabetes* **52** 1355–1363.
- Xiao B, Heath R, Saiu P, Leiper FC, Leone P, Jing C, Walker PA, Haire L, Eccleston JF, Davis CT *et al.* 2007 Structural basis for AMP binding to mammalian AMP-activated protein kinase. *Nature* **449** 496–500.
- Xue B & Kahn BB 2006 AMPK integrates nutrient and hormonal signals to regulate food intake and energy balance through effects in the hypothalamus and peripheral tissues. *Journal of Physiology* **574** 73–83.
- Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K *et al.* 2002 Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. *Nature Medicine* **8** 1288–1295.
- Yu X, McCorkle S, Wang M, Lee Y, Li J, Saha AK, Unger RH & Ruderman NB 2004 Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition. *Diabetologia* **47** 2012–2021.
- Zang M, Zuccollo A, Hou X, Nagata D, Walsh K, Herscovitz H, Brecher P, Ruderman NB & Cohen RA 2004 AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. *Journal of Biological Chemistry* **279** 47898–47905.
- Zbucki RL, Sawicki B, Hryniewicz A & Winnicka MM 2008 Cannabinoids enhance gastric X/A-like cells activity. *Folia Histochemistry and Cytobiology* **46** 219–224.
- Zheng D, MacLean PS, Pohnert SC, Knight JB, Olson AL, Winder WW & Dohm GL 2001 Regulation of muscle GLUT-4 transcription by AMP-activated protein kinase. *Journal of Applied Physiology* **91** 1073–1083.
- Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N *et al.* 2001 Role of AMP-activated protein kinase in mechanism of metformin action. *Journal of Clinical Investigation* **108** 1167–1174.
- Zong H, Ren JM, Young LH, Pypaert M, Mu J, Birnbaum MJ & Shulman GI 2002 AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. *PNAS* **99** 15983–15987.

Received in final form 26 June 2009

Accepted 22 July 2009

Made available online as an Accepted Preprint 22 July 2009